


## CL2E-SN38 TFA

**Cat. No.:** HY-139909A  
**Molecular Formula:** C<sub>89</sub>H<sub>117</sub>F<sub>3</sub>N<sub>14</sub>O<sub>26</sub>  
**Molecular Weight:** 1855.95  
**Target:** Drug-Linker Conjugates for ADC  
**Pathway:** Antibody-drug Conjugate/ADC Related  
**Storage:** 4°C, protect from light, stored under nitrogen  
 \* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (53.88 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	0.5388 mL	2.6940 mL	5.3881 mL
				5 mM	0.1078 mL	0.5388 mL	1.0776 mL
				10 mM	0.0539 mL	0.2694 mL	0.5388 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (1.35 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (1.35 mM); Clear solution						

### BIOLOGICAL ACTIVITY

Description	CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor <sup>[1]</sup> .
-------------	---

### REFERENCES

[1]. Lianqi Liu, et al. Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates. Drug Deliv. 2021 Dec;28(1):2603-2617.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA